N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC • ClinicalTrials.gov ID: NCT06136559

Registry updated: 2026-10-13
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.

Interventions

  • Nemtabrutinib (Drug)
    Administered orally
  • Ibrutinib (Drug)
    Administered orally
  • Acalabrutinib (Drug)
    Administered orally

Eligibility criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy. * Has at least 1 marker of disease burden. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization. * Has the ability to swallow and retain oral medication. * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization. * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening. * Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection. * Has gastrointestinal (GI) dysfunction that may affect drug absorption. * Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL. * Has had acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening. * Has clinically significant cardiovascular disease. * Has hypersensitivity to nemtabrutinib or contraindication to ibrutinib or acalabrutinib, or any of the excipients. * Has history of severe bleeding disorder. * Has known additional malignancy that is progressing or has required active treatment within the past 2 years. * Has received any systemic anticancer therapy for CLL/SLL. * Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors. * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. * Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration. * Has active infection requiring systemic therapy, including intravenous (IV) antibiotics during screening. * Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Conditions

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Locations

  • USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona, United States
  • Arizona Oncology Associates - NAHOA ( Site 8007) — Prescott, Arizona, United States
  • Alta Bates Summit Medical Center ( Site 0004) — Berkeley, California, United States
  • Moores Cancer Center ( Site 0003) — La Jolla, California, United States
  • Care Access - South Pasadena ( Site 0070) — Pasadena, California, United States
  • Saint Joseph Hospital ( Site 0026) — Denver, Colorado, United States
  • Lutheran Medical Center ( Site 0027) — Golden, Colorado, United States
  • Intermountain Health St. Mary's Regional Hospital ( Site 0025) — Grand Junction, Colorado, United States
  • Eastern CT Hematology & Oncology Associates ( Site 0033) — Norwich, Connecticut, United States
  • Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063) — Boca Raton, Florida, United States
  • Clermont Oncology Center ( Site 0046) — Clermont, Florida, United States
  • Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida, United States
  • Florida Cancer Specialists - East ( Site 7002) — West Palm Beach, Florida, United States
  • Saint Alphonsus Regional Medical Center ( Site 0067) — Boise, Idaho, United States
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0002) — Fort Wayne, Indiana, United States
  • University of Iowa Health Care. ( Site 0017) — Iowa City, Iowa, United States
  • University of Iowa Health Care. ( Site 0057) — Waukee, Iowa, United States
  • Saint Elizabeth Healthcare ( Site 0041) — Edgewood, Kentucky, United States
  • Owensboro Medical Health System ( Site 0066) — Owensboro, Kentucky, United States
  • Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) — Grand Rapids, Michigan, United States
  • Regions Hospital ( Site 0042) — Saint Louis Park, Minnesota, United States
  • MidAmerica Cancer Care, LLC ( Site 0043) — Kansas City, Missouri, United States
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052) — Billings, Montana, United States
  • Summit Medical Group Cancer Center ( Site 0007) — Florham Park, New Jersey, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016) — Hackensack, New Jersey, United States
  • New York Oncology Hematology, P.C. ( Site 0069) — Albany, New York, United States
  • Roswell Park Cancer Institute ( Site 0023) — Buffalo, New York, United States
  • RPCI Oncology, PC- Northtowns ( Site 0061) — Williamsville, New York, United States
  • Carolina Oncology Specialists, PA ( Site 0054) — Charlotte, North Carolina, United States
  • Southeastern Medical Oncology Center ( Site 0049) — Goldsboro, North Carolina, United States
  • Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002) — Broomall, Pennsylvania, United States
  • Cancer Care Associates Of York ( Site 0005) — York, Pennsylvania, United States
  • Tennessee Oncology-Chattanooga ( Site 0045) — Chattanooga, Tennessee, United States
  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031) — Nashville, Tennessee, United States
  • Texas Oncology - Central/South Texas ( Site 8008) — Austin, Texas, United States
  • The Center for Cancer and Blood Disorders ( Site 0032) — Fort Worth, Texas, United States
  • Texas Oncology - San Antonio ( Site 8006) — San Antonio, Texas, United States
  • Texas Oncology - Northeast Texas ( Site 8012) — Tyler, Texas, United States
  • University of Virginia Cancer Center ( Site 0040) — Charlottesville, Virginia, United States
  • Inova Schar Cancer Institute ( Site 0015) — Fairfax, Virginia, United States
  • Virginia Commonwealth University (VCU) Medical Center ( Site 0030) — Richmond, Virginia, United States
  • Swedish Cancer Institute, Edmonds Campus ( Site 0072) — Edmonds, Washington, United States
  • Swedish Cancer Institute, Issaquah Campus ( Site 0073) — Issaquah, Washington, United States
  • Swedish Medical Center-Swedish Cancer Institute ( Site 0071) — Seattle, Washington, United States
  • Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010) — Spokane, Washington, United States
  • SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048) — Madison, Wisconsin, United States
  • University Hospital and UW Health Clinics ( Site 0006) — Madison, Wisconsin, United States
  • Royal North Shore Hospital ( Site 2806) — St Leonards, New South Wales, Australia
  • AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0205) — Mechelen, Antwerpen, Belgium
  • UZ Leuven-Hematology ( Site 0200) — Leuven, Vlaams-Brabant, Belgium
  • Hospital Erasto Gaertner ( Site 2212) — Curitiba, Paraná, Brazil
  • Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 2211) — Ribeirão Preto, São Paulo, Brazil
  • Hospital 9 De Julho ( Site 2206) — São Paulo, São Paulo, Brazil
  • Instituto Nacional de Câncer - INCA ( Site 2201) — Rio de Janeiro, Brazil
  • Hospital Paulistano-Americas Oncologia ( Site 2202) — São Paulo, Brazil
  • BC Cancer Kelowna ( Site 0112) — Kelowna, British Columbia, Canada
  • BC Cancer Victoria ( Site 0109) — Victoria, British Columbia, Canada
  • William Osler Health System ( Site 0103) — Brampton, Ontario, Canada
  • The Ottawa Hospital - General Campus ( Site 0102) — Ottawa, Ontario, Canada
  • McGill University Health Centre ( Site 0106) — Montreal, Quebec, Canada
  • Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski ( Site 0100) — Rimouski, Quebec, Canada
  • FALP-UIDO ( Site 2300) — Santiago, Region M. de Santiago, Chile
  • Clínica Alemana de Santiago-Unidad de Investigaciones ( Site 2306) — Santiago, Region M. de Santiago, Chile
  • Bradfordhill-Clinical Area ( Site 2310) — Santiago, Region M. de Santiago, Chile
  • Anhui Provincial Cancer Hospital ( Site 2001) — Hefei, Anhui, China
  • Peking University First Hospital ( Site 2022) — Beijing, Beijing Municipality, China
  • Peking University Third Hospital-Hematology ( Site 2011) — Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 2041) — Chongqing, Chongqing Municipality, China
  • Sun Yat-sen University Cancer Center ( Site 2028) — Guangzhou, Guangdong, China
  • Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 2006) — Guangzhou, Guangdong, China
  • Liuzhou People's Hospital ( Site 2029) — Liuzhou, Guangxi, China
  • Guangxi Medical University Affiliated Tumor Hospital ( Site 2004) — Nanning, Guangxi, China
  • The Affiliated Hospital of Guizhou Medical University ( Site 2024) — Guiyang, Guizhou, China
  • Hainan General Hospital ( Site 2018) — Haikou, Hainan, China
  • Henan Cancer Hospital-hematology department ( Site 2025) — Zhengzhou, Henan, China
  • Tongji Hospital Affiliated to Tongji Medical College of HUST ( Site 2016) — Wuhan, Hubei, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2015) — Wuhan, Hubei, China
  • Hunan Cancer Hospital ( Site 2020) — Changsha, Hunan, China
  • The Second Xiangya Hospital of Central South University ( Site 2010) — Changsha, Hunan, China
  • Jiangsu Province Hospital ( Site 2000) — Nanjing, Jiangsu, China
  • The First Affliated Hospital of Suzhou University ( Site 2027) — Suzhou, Jiangsu, China
  • The Affiliated Hospital of Xuzhou Medical College ( Site 2013) — Xuzhou, Jiangsu, China
  • The First Affiliated Hospital of Nanchang University ( Site 2023) — Nanchang, Jiangxi, China
  • Jiangxi Provincial Cancer Hospital ( Site 2009) — Nanchang, Jiangxi, China
  • The First Hospital of Jilin University-Hematology ( Site 2030) — Changchun, Jilin, China
  • Shaanxi provincial people's hospital ( Site 2012) — Xi'an, Shaanxi, China
  • Shandong Cancer Hospital ( Site 2003) — Jinan, Shandong, China
  • Shanxi Cancer Hospital ( Site 2033) — Taiyuan, Shanxi, China
  • West China Hospital, Sichuan University-Head and Neck Oncology ( Site 2026) — Chengdu, Sichuan, China
  • Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 2019) — Tianjin, Tianjin Municipality, China
  • Institute of hematology&blood disease hospital-Lymphoma ( Site 2005) — Tianjin, Tianjin Municipality, China
  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2014) — Ürümqi, Xinjiang, China
  • The first Affiliated Hospital, Zhejiang University School of Medicine-Hematology ( Site 2002) — Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital ( Site 2017) — Hangzhou, Zhejiang, China
  • Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 2405) — Valledupar, Cesar Department, Colombia
  • IMAT S.A.S ( Site 2401) — Montería, Departamento de Córdoba, Colombia
  • Fundacion Valle del Lili- CIC-Oncology CIC ( Site 2402) — Cali, Valle del Cauca Department, Colombia
  • Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0301) — Hradec Králové, Czechia
  • Fakultni nemocnice Olomouc ( Site 0303) — Olomouc, Czechia
  • Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302) — Prague, Czechia
  • Aalborg Universitetshospital, Syd ( Site 0403) — Aalborg, North Denmark, Denmark
  • Sjællands Universitetshospital Køge ( Site 0402) — Koege, Region Sjælland, Denmark
  • Odense Universitetshospital-Department of Hematology ( Site 0401) — Odense C, Region Syddanmark, Denmark
  • Universitaetsklinikum Ulm. ( Site 0601) — Ulm, Baden-Wurttemberg, Germany
  • VK&K Studien GbR ( Site 0607) — Landshut, Bavaria, Germany
  • Kliniken Maria Hilf ( Site 0603) — Mönchengladbach, North Rhine-Westphalia, Germany
  • InVO Institut für Versorgungsforschung in der Onkologie ( Site 0606) — Koblenz, Rhineland-Palatinate, Germany
  • Universitätsklinikum Halle ( Site 0604) — Halle, Saxony-Anhalt, Germany
  • Onkologische Schwerpunktpraxis Kurfuerstendamm ( Site 0600) — Berlin, Germany
  • Evangelismos General Hospital of Athens ( Site 0700) — Athens, Attica, Greece
  • General Hospital of Athens "Laiko" ( Site 0704) — Athens, Attica, Greece
  • University Hospital of Alexandroupolis ( Site 0701) — Alexandroupoli, East Macedonia and Thrace, Greece
  • University Hospital of Ioannina ( Site 0702) — Ioannina, Greece
  • Queen Mary Hospital ( Site 3300) — Hong Kong, Hong Kong
  • Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 1503) — Haifa, Israel
  • Bnai Zion Medical Center ( Site 1505) — Haifa, Israel
  • Hadassah Medical Center-Hemato-Oncology ( Site 1500) — Jerusalem, Israel
  • Galilee Medical Center ( Site 1507) — Nahariya, Israel
  • Rabin Medical Center ( Site 1504) — Petah Tikva, Israel
  • Sheba Medical Center-Hemato Oncology ( Site 1501) — Ramat Gan, Israel
  • Yitzhak Shamir Medical Center. ( Site 1506) — Ẕerifin, Israel
  • Nagoya University Hospital ( Site 1907) — Nagoya, Aichi-ken, Japan
  • Gunma University Hospital ( Site 1903) — Maebashi, Gunma, Japan
  • Hokkaido University Hospital ( Site 1900) — Sapporo, Hokkaido, Japan
  • Kobe City Medical Center General Hospital ( Site 1910) — Kobe, Hyōgo, Japan
  • Tohoku University Hospital ( Site 1901) — Sendai, Miyagi, Japan
  • Kindai University Hospital ( Site 1909) — Sakai, Osaka, Japan
  • Shimane University Hospital ( Site 1911) — Izumo, Shimane, Japan
  • Cancer Institute Hospital of JFCR ( Site 1906) — Koto, Tokyo, Japan
  • Chiba Cancer Center ( Site 1905) — Chiba, Japan
  • Kyushu University Hospital ( Site 1914) — Fukuoka, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 1913) — Hiroshima, Japan
  • Okayama University Hospital ( Site 1912) — Okayama, Japan
  • Japanese Red Cross Osaka Hospital ( Site 1908) — Osaka, Japan
  • Yamagata University Hospital ( Site 1902) — Yamagata, Japan
  • University Malaya Medical Centre ( Site 1604) — Lembah Pantai, Kuala Lumpur, Malaysia
  • Hospital Pulau Pinang ( Site 1602) — George Town, Pulau Pinang, Malaysia
  • Queen Elizabeth Hospital ( Site 1603) — Kota Kinabalu, Sabah, Malaysia
  • Grupo Médico ASSET SC ( Site 2611) — Benito Juárez, Mexico City, Mexico
  • Centro de Infusion Superare ( Site 2602) — Mexico City, Mexico City, Mexico
  • Health Pharma Professional Research S.A. de C.V: ( Site 2608) — Mexico City, Mexico City, Mexico
  • Waikato Hospital-Haematology ( Site 3202) — Hamilton, Waikato Region, New Zealand
  • North Shore Hospital-Department of Haematology ( Site 3200) — Auckland, New Zealand
  • Aotearoa Clinical Trials ( Site 3201) — Auckland, New Zealand
  • Akershus Universitetssykehus ( Site 0902) — Lørenskog, Akershus, Norway
  • Sykehuset i Vestfold ( Site 0903) — Tønsberg, Vestfold, Norway
  • Oslo Universitetssykehus Rikshospitalet-Avdeling for blodsykdommer ( Site 0901) — Oslo, Norway
  • Centro Medico Monte Carmelo-Oncology ( Site 2706) — Arequipa, Ariqipa, Peru
  • Clínica Anglo Americana ( Site 2701) — Lima, Peru
  • Pratia MCM Krakow ( Site 1007) — Krakow, Lesser Poland Voivodeship, Poland
  • Uniwersytecki Szpital Kliniczny nr 1 w Lublinie-Oddział Hematoonkologii-Transplantacji Szpiku i Chem ( Site 1006) — Lublin, Lublin Voivodeship, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1004) — Warsaw, Masovian Voivodeship, Poland
  • Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 1011) — Gdansk, Pomeranian Voivodeship, Poland
  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oddział Hematologii i Transplantacji ( Site 1013) — Słupsk, Pomeranian Voivodeship, Poland
  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1000) — Gliwice, Silesian Voivodeship, Poland
  • Pratia Onkologia Katowice ( Site 1009) — Katowice, Silesian Voivodeship, Poland
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Site 1005) — Olsztyn, Warmian-Masurian Voivodeship, Poland
  • Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3103) — Lisbon, Lisbon District, Portugal
  • Champalimaud Foundation ( Site 3102) — Lisbon, Lisbon District, Portugal
  • Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 3107) — Vila Nova de Gaia, Porto District, Portugal
  • Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3104) — Lisbon, Portugal
  • Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3106) — Lisbon, Portugal
  • Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3100) — Porto, Portugal
  • Wits Clinical Research ( Site 1102) — Johannesburg, Gauteng, South Africa
  • Netcare Pretoria East Hospital-Alberts Cellular Therapy ( Site 1101) — Pretoria, Gauteng, South Africa
  • Groote Schuur Hospital-Clinical Haematology ( Site 1100) — Cape Town, Western Cape, South Africa
  • Haemalife ( Site 1105) — Kuilsriver, Western Cape, South Africa
  • Constantiaberg Haematology ( Site 1106) — Plumstead, Western Cape, South Africa
  • Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 1207) — L'Hospitalet Del Llobregat, Barcelona, Spain
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 1202) — Barcelona, Catalonia, Spain
  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1209) — Pozuelo de Alarcón, Madrid, Spain
  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 1208) — Majadahonda, Madrid, Comunidad de, Spain
  • hospital universitario de canarias ( Site 1205) — San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1206) — Barcelona, Spain
  • Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 1201) — Salamanca, Spain
  • Karolinska Universitetssjukhuset Solna ( Site 1302) — Stockholm, Stockholm County, Sweden
  • Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 1702) — Kaohsiung City, Taiwan
  • National Cheng Kung University Hospital ( Site 1700) — Tainan, Taiwan
  • National Taiwan University Hospital ( Site 1701) — Taipei, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch ( Site 1703) — Taoyuan, Taiwan
  • Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 1801) — Bangkok, Bangkok, Thailand
  • Chulalongkorn University ( Site 1802) — Pathumwan, Bangkok, Thailand
  • Naresuan University Hospital ( Site 1804) — Muang, Changwat Phitsanulok, Thailand
  • Songklanagarind hospital ( Site 1803) — Hat Yai, Changwat Songkhla, Thailand
  • Maharaj Nakorn Chiang Mai Hospital ( Site 1800) — Muang, Chiang Mai, Thailand
  • Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 1401) — Ankara, Turkey (Türkiye)
  • Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1407) — Ankara, Turkey (Türkiye)
  • Antalya Egitim ve Arastırma Hastanesi ( Site 1409) — Antalya, Turkey (Türkiye)
  • Trakya University Medical Faculty Hospital-Hematology ( Site 1403) — Edirne, Turkey (Türkiye)
  • Mega Medipol ( Site 1412) — Istanbul, Turkey (Türkiye)
  • Sisli Florence Nightingale Hastanesi ( Site 1411) — Istanbul, Turkey (Türkiye)
  • Marmara Universitesi Pendik Egitim Arastirma Hastanesi ( Site 1408) — Istanbul, Turkey (Türkiye)
  • Ege Universitesi Hastanesi ( Site 1404) — Izmir, Turkey (Türkiye)
  • Ondokuz Mays Üniversitesi ( Site 1410) — Samsun, Turkey (Türkiye)
  • Southmead Hospital ( Site 3010) — Bristol, Bristol, City of, United Kingdom
  • Royal Lancaster Infirmary ( Site 3012) — Lancaster, Lancashire, United Kingdom
  • St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3006) — London, London, City of, United Kingdom
  • The Churchill Hospital ( Site 3007) — Oxford, Oxfordshire, United Kingdom
  • GenesisCare - Bristol ( Site 3011) — Bristol, South Gloucestershire, United Kingdom
  • GenesisCare - Cambridge ( Site 3001) — Newmarket, Suffolk, United Kingdom
  • GenesisCare - Windsor ( Site 3002) — Windsor, Windsor And Maidenhead, United Kingdom
  • Barnet Hospital ( Site 3005) — Barnet, United Kingdom
  • St James's University Hospital ( Site 3004) — Leeds, United Kingdom
  • City Hospital, Nottingham University Hospitals NHS Trust ( Site 3003) — Nottingham, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record